Faraday Pharmaceuticals

Faraday Pharmaceuticals, Inc. was a Seattle, Washington clinical-stage biopharmaceutical company founded in 2014 as a spinout of Fred Hutchinson Cancer Center, built on the elemental-reducing-agent research of Dr. Mark Roth. It developed therapies intended to prevent and treat cardiac and skeletal muscle loss after acute critical illness, led by FDY-5301 — a proprietary intravenous formulation of sodium iodide designed to neutralize reactive oxygen species and limit reperfusion injury in patients undergoing percutaneous coronary intervention for anterior ST-elevation myocardial infarction (STEMI). The company raised roughly $120M from an investor group led by ARCH Venture Partners and Polaris Partners. Its Phase 3 trial read out in late 2025 and failed to meet its primary or secondary endpoints, and Faraday announced in February 2026 that it had ceased operations and was winding down the business. Faraday never operated a developer program, public API, SDK, or machine-readable specification, and its faradaypharma.com website is no longer served. This profile is retained as a historical record; there is no API surface to enrich.

Faraday Pharmaceuticals is profiled on the APIs.io network. Tagged areas include Company, Pharmaceuticals, Biotechnology, Life Sciences, and Clinical Trials.

🌐 Visit website 📡 Source on GitHub
5.1/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-17 · rubric v0.11.0
0 APIs
CompanyPharmaceuticalsBiotechnologyLife SciencesClinical TrialsClinical StageCardiologyDrug DevelopmentDefunct

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-17 · rubric v0.11.0
Composite quality — 5.1/100 · minimal
Contract Quality 0.0 / 21
Developer Ergonomics 0.0 / 17
Commercial Clarity 0.0 / 17
Operational Transparency 0.0 / 11
Governance 0.0 / 10
Discoverability 3.9 / 9
Regulatory Posture 1.1 / 15
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/faraday-pharmaceuticals: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Faraday Pharmaceuticals Domain Security

TLSv1.3 · HSTS · DMARC

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Company 1

The organization behind the API

LinkedIn
LinkedIn

Other 1

Properties that don't map to a standard resource type

SecondaryMarket
SecondaryMarket

Source (apis.yml)

apis.yml Raw ↑ 
aid: faraday-pharmaceuticals
name: Faraday Pharmaceuticals
description: Faraday Pharmaceuticals, Inc. was a Seattle, Washington clinical-stage biopharmaceutical company founded in 2014
  as a spinout of Fred Hutchinson Cancer Center, built on the elemental-reducing-agent research of Dr. Mark Roth. It developed
  therapies intended to prevent and treat cardiac and skeletal muscle loss after acute critical illness, led by FDY-5301 —
  a proprietary intravenous formulation of sodium iodide designed to neutralize reactive oxygen species and limit reperfusion
  injury in patients undergoing percutaneous coronary intervention for anterior ST-elevation myocardial infarction (STEMI).
  The company raised roughly $120M from an investor group led by ARCH Venture Partners and Polaris Partners. Its Phase 3 trial
  read out in late 2025 and failed to meet its primary or secondary endpoints, and Faraday announced in February 2026 that
  it had ceased operations and was winding down the business. Faraday never operated a developer program, public API, SDK,
  or machine-readable specification, and its faradaypharma.com website is no longer served. This profile is retained as a
  historical record; there is no API surface to enrich.
url: https://raw.githubusercontent.com/api-evangelist/faraday-pharmaceuticals/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: defunct-no-api-surface
x-status: defunct
x-founded: '2014'
x-shutdown-date: 2026-02
x-shutdown-reason: FDY-5301 Phase 3 missed its primary and secondary endpoints; the company announced in February 2026 that
  it had ceased operations and was winding down.
x-domain-status: expired-hosting
x-domain-note: faradaypharma.com still resolves to Squarespace and retains live SPF/DMARC mail records, but every path — including
  / — returns HTTP 404 with the Squarespace "Website Expired" page. The domain is deliberately NOT wired as a Website pointer
  because it no longer serves company content.
specificationVersion: '0.20'
created: '2026-08-04'
modified: '2026-08-04'
tags:
- Company
- Pharmaceuticals
- Biotechnology
- Life Sciences
- Clinical Trials
- Clinical Stage
- Cardiology
- Drug Development
- Defunct
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: LinkedIn
  url: https://www.linkedin.com/company/faradaypharma
- type: SecondaryMarket
  url: https://forgeglobal.com/faraday-pharmaceuticals_stock/
- type: DomainSecurity
  url: security/faraday-pharmaceuticals-domain-security.yml
x-enrichment:
  date: '2026-08-04'
  status: minimal
  artifacts_added: 3
  pass: local-v1